Citing Our Work

Dr. Gyawali has been quoted/cited in many press and online media, some of which are listed below:

• Medscape. New Cancer Drugs: Do Patients Prefer Faster Access or Clinical Benefit?

• Medscape. Accelerated Approval Pathway for Cancer Drugs: Does It Work?.

• Oncology News Central. New Standard in Melanoma May Save $1 Billion While Improving Lives

• Medscape. Should Cancer Trial Eligibility Become More Inclusive?

• The Walrus. Are We Losing the War on Cancer?

• OBR Oncology. Does FDA Withdrawal of Cancer Drug Show Bigger Changes Needed?

• Bloomberg. FDA Debates Fate of a $900,000 Cancer Drug That May Not Work.

• Undark. The Side Effect Roulette of Cancer Treatment

• Decoder: The world wages war on cancer

• Nature. How a controversial US drug policy could be harming cancer patients worldwide

• Medscape. New Global Initiative Aims to Reform Cancer Trials and Care

• Undark. Will New FDA Rules Help Dial Back Expedited Drugs?

• The Lancet. Cancer care: widening the scope of innovation.

• Nature. Cancer ‘moonshot’ has lofty new goal: halve deaths in 25 years.

• Cancer World. Examples of Telemedicine Application Worldwide.

• Cancer World. North and South ‒ learning faster means learning together

• STAT News. Cancer drug indications remain on labels even after trials fail to confirm their benefits.

• RAPS. FDA defends Aduhelm’s accelerated approval, while others call for reform.

• Bloomberg News. Alzheimer’s Drug Discord Puts FDA Accelerated System Under Fire.

• Nature Reviews. Accelerated approvals under the microscope.

• FDA faces tough choice after panel backs speedy cancer drug approvals.

• Medscape. FDA Targets Cancer Indications That Fail to Prove Clinical Benefit.

• ESMO Perspectives. What role for real-world evidence in cancer research?. March 1, 2021.

• IASLC News. Examining Value and Access in Lung Cancer Care, From Screening to Treatment. Jan 26, 2021.

• ASCO Daily News. Addressing Mental Distress Among Health Care Workers During COVID-19: How to Better Support the Oncology Workforce. Dec 9, 2020.

• Are higher prices of anticancer medicines reflected in better outcomes for patients?

• Should You Risk Covid-19 to Get Routine Health Screenings?

• Financial toxicity a lingering, often unexpected burden for cancer survivors

• Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction?

• Do Oncologists Change Practice Based on Inadequate Evidence?

• In a Disease of Aging, Patients in Trials Get Younger and Younger

• Cosa è importante per un paziente con il cancro?

• Nivolumab plus ipilimumab extends overall survival in non-small cell lung cancer patients

• Do Oncologists Change Practice Based on Inadequate Evidence?

• What Do Surrogate End Points Actually Predict?

• Top Hope Among Advanced Cancer Patients Is Not Cure

• SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC

• Cancer Moonshot Takes Aim at Smoking

• MSKCC Risk Stratification Model in RCC Updated to Include Genomic Information

• Breaking Down Breakthrough Cancer Therapies

• Investigators Question the Use of PFS as a Surrogate End Point

• Adjuvant Sunitinib in Renal Cell Carcinoma May Increase Symptoms, Reduce Health Quality Scores

• Novel Surrogate End Point Proposed in Hepatocellular Carcinoma

• Atezolizumab Powers Up in NSCLC

• Cost of Cancer Drugs: Something Has To Give

• Drugs Approved Under the Breakthrough Therapy Pathway Lack Basic Features of High-Quality Trials

• Pharma banks on cancer patients who are ‘determined to keep fighting’

• Onclive. It’s Fast-Forward for Cancer Drugs.

• Pfizer cranks up Parp breast cancer battle

• SciDevNet. Is Cancer Control in Poor Countries Too High-Tech?

• Analysis: As Biosimilar Of Key Cancer Drug Spreads, Where Is The Price Reduction?

• Medpage Today. Keynote 028 Data Helps PD-1 inhibitor find footing in SCLC.

• Medpage Today. CT surveillance in Resected NSCLC: Time for a Sea Change?

• Medpage Today. SCLC: The Ups and Downs of an Angiogenesis Inhibitor.

Dr. Gyawali’s academic work and publications have been quoted/cited in various international media, some of which are listed below:

• Public Dollars, Private Profits? Cancer Drug’s Cost Sky High Despite Taxpayer Funding

• Oncology Group Fighting to Change Cancer Drug Approvals

• Oncology News Central. Stronger Rules Needed for Oncology Financial Conflicts of Interest, Critics Argue

• Regulatory Focus. RAPS. Perspective: FDA’s accelerated approval guidance doesn’t go far enough

• ESMO Daily Reporter. Preventive immunotherapy shows some activity in pre-cancer oral lesions

• OBR Oncology. Controversy Over Crossover Access in Clinical Trials: Should Changes Be Mandated?

• FDA’s accelerated approval guidance doesn’t go far enough

• Spontaneous Cancer Regression Extremely Rare

• A Farewell to Arms? Drug Approvals Based on Single-Arm Trials Can Be Flawed

• Dubious’ Benefit of Abemaciclib in Early Breast Cancer

• Forget Moonshot: Cancer Patients Right Now Need ‘Groundshot’

• Cancer Researchers Aren’t Reporting Quality of Life Outcomes Accurately

• F.D.A. Rushed a Drug for Preterm Births. Did It Put Speed Over Science?

• European Cancer Summit 2021 Report: From Plans to Action

• Medscape. FDA Defends Alzheimer Drug Approval, Others Call It a ‘9/11 Moment’ for Medicare

• AP. FDA to scrutinize unproven cancer drugs after 10-year gap

• Is FDA Getting It Right on Cancer Drug Approvals?

• US Cancer Drug Approvals Ensure Access but Not Value

• Analysis of Ramucirumab Suggests Risks Outweigh Benefits

• Could COVID-19 Winnow Out Low-Value Cancer Care?

• An FDA tool for hastening approvals is not very useful for breast cancer drugs

• FDA Guidance on Surrogate Endpoints Lacks Specificity

• Targeted Therapy Response Rates, Duration of Responses in Randomized vs Non-Randomized Trials

• How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?

• Overall Survival Remains ‘Gold Standard’ For PD-1 Inhibitor Trial Endpoints

• Knowing the Appropriateness of Running Noninferiority Trials in Oncology

• A Double Whammy of Non-Good News About Non-Inferiority Trials

• My JAMA Internal Medicine article on accelerated approval of cancer drugs was covered by 60 news outlets, all of which can be accessed here.
  • This was also covered by the CNN and NPR.

• How Could We Fail so Miserably?’ Real-World Evidence Offers Sobering Reality

• Accused: Surrogate Endpoints, Non-Inferiority Trials for Cancer Drugs

• Downplaying Drug Toxicity in Oncology Clinical Trials

• Progression-Free Survival and Patient Quality of Life Are Not One and the Same

• When medicine & media sugarcoat the true impact of patient harms

• Cancer drug trial studies urged to report harms transparently

• Are Sponsors Downplaying Risks of Cancer Drugs?

• The toxicity of the treatment was acceptable. But acceptable for whom?

• Only you can decide if a Drug’s Risk is Acceptable.

• FDA’s Accelerated Approval Pathway Needs Active Management

• Association between age and sex and mortality after adjuvant therapy for renal cancer.

• Plasma-Based Genotyping Enhances Personalized Therapy of Metastatic Lung Cancer

• PD-1 Inhibitors Appear to Improve Overall Survival More than Progression-Free Cancer

• Four months free of chemo or six months with it?

• Medscape Oncology. Cancer Groundshot has Pragamatic Aims.  

• ecancer. The case for a global cancer groundshot

• Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers

• Cancer Therapy Advisor. Curbing Regulatory Capture: A Q&A with Dr. Bishal Gyawali

• Medscape Oncology. ‘Intriguing’: 9 Weeks of Trastuzumab for Breast Cancer

• Medscape Oncology. Case Closed on <1 Year of Trastuzumab for Breast Cancer

• Medscape Oncology. Not Legit? The Superiority of Pemetrexed in Lung Cancer.

• Cancer Therapy Advisor. Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

• Medscape Oncology. Reduce Cancer Care Costs by Avoiding ‘Low-Value’ Options